Literature DB >> 11751683

Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes.

D H Gutmann1, Y L Wu, N M Hedrick, Y Zhu, A Guha, L F Parada.   

Abstract

Individuals with the neurofibromatosis 1 (NF1) tumor predisposition syndrome develop low-grade pilocytic astrocytomas at an increased frequency. Previously, we demonstrated that astrocytes from mice heterozygous for a targeted mutation in the Nf1 gene (Nf1+/- astrocytes) exhibit a cell autonomous growth advantage associated with increased RAS pathway activation. In this report, we extend our initial characterization of the effect of reduced Nf1 gene expression on astrocyte function by demonstrating that Nf1+/- astrocytes exhibit decreased cell attachment, actin cytoskeletal abnormalities during the initial phases of cell spreading, and increased cell motility. Whereas these cytoskeletal abnormalities were also observed in Nf1-/- astrocytes, astrocytes expressing a constitutively active RAS molecule showed increased cell motility and abnormal actin cytoskeleton organization during cell spreading, but exhibited normal cell attachment. Based on ongoing gene expression profiling experiments on human astrocytoma tumors, we demonstrate increased expression of two proteins implicated in cell attachment, spreading and motility (GAP43 and T-cadherin) in Nf1+/- and Nf1-/- astrocytes. These results support the emerging notion that tumor suppressor gene heterozygosity results in abnormalities in cell function that may contribute to the pathogenesis of non-tumor phenotypes in NF1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751683     DOI: 10.1093/hmg/10.26.3009

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  16 in total

Review 1.  Mouse models of inherited cancer syndromes.

Authors:  Sohail Jahid; Steven Lipkin
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

Review 2.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

Review 3.  Neuropathology for the neuroradiologist: Antoni A and Antoni B tissue patterns.

Authors:  F J Wippold; M Lubner; R J Perrin; M Lämmle; A Perry
Journal:  AJNR Am J Neuroradiol       Date:  2007-09-24       Impact factor: 3.825

4.  Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.

Authors:  Jessica J Hawes; Robert G Tuskan; Karlyne M Reilly
Journal:  Neurogenetics       Date:  2007-01-11       Impact factor: 2.660

5.  Partial Blindness to Submicron Topography in NF1 Haploinsufficient Cultured Fibroblasts Indicates a New Function of Neurofibromin in Regulation of Mechanosensoric.

Authors:  D Kaufmann; J Hoesch; Y Su; L Deeg; K Mellert; J P Spatz; R Kemkemer
Journal:  Mol Syndromol       Date:  2012-09-27

6.  Targeting neovascular pericytes in neurofibromatosis type 1.

Authors:  Ugur Ozerdem
Journal:  Angiogenesis       Date:  2005-05-09       Impact factor: 9.596

7.  Oligodendrocyte progenitor cell numbers and migration are regulated by the zebrafish orthologs of the NF1 tumor suppressor gene.

Authors:  Jeong-Soo Lee; Arun Padmanabhan; Jimann Shin; Shizhen Zhu; Feng Guo; John P Kanki; Jonathan A Epstein; A Thomas Look
Journal:  Hum Mol Genet       Date:  2010-09-21       Impact factor: 6.150

8.  Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.

Authors:  Navneet Sangha; Rong Wu; Rork Kuick; Scott Powers; David Mu; Diane Fiander; Kit Yuen; Hidetaka Katabuchi; Hironori Tashiro; Eric R Fearon; Kathleen R Cho
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

9.  Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells.

Authors:  Yuan Huang; Fatima Rangwala; Patricia C Fulkerson; Bo Ling; Erin Reed; Adrienne D Cox; John Kamholz; Nancy Ratner
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

10.  Mouse models of neurofibromatosis 1 and 2.

Authors:  David H Gutmann; Marco Giovannini
Journal:  Neoplasia       Date:  2002 Jul-Aug       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.